Clinical Trial Update: Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Omega-3 fatty acids (Omacor) for IgA nephropathy has completed, with reported efficacy and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Omacor (omega-3-acid ethyl esters)

Snippet

Sponsor: Kuhnil Pharmaceutical Co., Ltd. | Conditions: IgA Nephropathy | Phase 3 | Status: COMPLETED